Britain and America have forged a important commercial pact that will guarantee no duties on UK pharmaceutical exports being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to increase funding on medicines through the National Health Service (NHS). This move guarantees that duties on these key goods will stay at zero for a period of three years.
This development follows recent threats to dramatically increase duties on branded pharmaceutical products, with potential rates discussed up to double the cost.
"This agreement between the UK strengthens the international landscape for cutting-edge drugs and introduces much-needed balance to American-British drug exports," a release said.
Economic Impact
Drugs represent one of the UK's largest export categories to the America, which is by far the biggest buyer for large companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period prior to September, the UK exported pharmaceutical products valued at £11.1bn to the US. This amount accounted for 17.4% of all goods exports in that period.
"This guarantee secures employment, increases funding and paves the way for the UK to become a international leader for medical research," a government official stated.
Specific British Pledges
The deal entails several specific changes from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it deems new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a target to raise total public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Last year, refunds topped twenty percent.
Broader Context
This agreement comes amid a protracted dispute between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
This friction were intensified by claims that US consumers were charged significantly more for the identical medicines than patients in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or abandoned, while substantial funding commitments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS had to spend more on medicines, noting that its spending on drugs had decreased as a percentage of its total funding over the previous ten-year period.
